Developed by Bernard Attali and Asher Peretz, MD, of the Sackler Faculty of Medicine, the medication, known as BL-7050, inhibits the transmission of pain signals throughout the body. In experiments measuring electrical activity of neurons, the drug has been shown to prevent the hyper-excitability of neurons, protecting against neuropathic pain and epileptic seizures.
Related Articles on Pain Management:
Study Sheds Doubt on Steroid Injections for Back Pain
Wisconsin to Have Statewide Drug Monitoring System
Most Patients Take Incorrect Dosages of Prescription Drugs
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
